Conclusion GLP-1RAs show significant promise as a potential disease-modifying therapy for neurodegenerative and inflammatory eye diseases, acting through both systemic metabolic improvements and direct ocular mechanisms, representing a paradigm shift beyond their metabolic indications
Clinical investigations and reviews have described changes in glucose-related biomarkers, lipid fractions, blood pressure measurements, and other cardiometabolic parameters when the peptide is evaluated in controlled settings
Efficacy and safety of antidiabetic agents for major depressive disorder and bipolar depression: a meta-analysis of randomized, double-blind, placebo-controlled trials
The brains Geppetto-microbes as puppeteers of neural function and behaviour
The dose should only be increased by a medical professional
If someone has very high cholesterol, or has already had a heart attack or stroke, statins are usually needed